CytaCoat AB is a Swedish company founded by researchers from Karolinska Institute and KTH with a mission to develop antibacterial coating technology for medical devices. The company's proprietary polymer surface repels bacteria from the surface of medical devices, preventing healthcare-associated infections. CytaCoat's antibacterial coating technology is stable towards variations in pH and ionic strength and prevents the release of components with potentially toxic or accumulation, making it a safer alternative to antibiotics. The company has a fully equipped laboratory in the Karolinska Institutet Science Park for microbiology evaluation, optimisation of the CytaCoat technology, and pilot plant production. CytaCoat has also established contacts with clinical collaborators at Karolinska University Hospital Neonatal Unit and the Division of Clinical Microbiology. The company cooperates with experienced consultants in regulatory, clinical research organisations, patent experts, and providers of specialist analyses to transform their innovation into a fully viable commercial product.